No connection

Search Results

Earnings Score 45 Bearish

Moderna Reports Q1 Revenue Surge Amid Continued Heavy Losses

May 01, 2026 14:53 UTC
MRNA
Short term

Moderna significantly exceeded first-quarter revenue expectations driven by a spike in international vaccine sales. Despite the top-line growth, the company posted a substantial net loss, weighing on share price.

  • Q1 revenue reached $389 million, up from $108 million YoY
  • Revenue exceeded analyst estimates of $236.4 million
  • Company reported a net loss of $1.34 billion
  • Earnings per share (EPS) loss stood at $3.40
  • International vaccine demand served as the primary growth catalyst

Moderna reported a sharp increase in first-quarter revenue, defying previous expectations of a slowdown in Covid-19 vaccine demand. The growth was primarily underpinned by a surge in international sales, allowing the company to outperform market forecasts. Financial results for the quarter show revenue more than tripling to $389 million, compared to $108 million during the same period last year. This performance handily beat the $236.4 million anticipated by analysts. However, the revenue growth was offset by significant operational costs and losses. Moderna logged a net loss of $1.34 billion for the quarter, which equates to a loss of $3.40 per share. Despite the positive revenue surprise, the stock has faced downward pressure. Investors appear focused on the company's bottom-line struggles and the sustainability of vaccine-driven growth as the firm navigates its post-pandemic financial transition.

Sign up free to read the full analysis

Create a free account to unlock full AI-curated market articles, personalized alerts, and more.

Share this article

Related Articles

Stay Ahead of the Markets

Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.

Home
Terminal
AI Chat
Markets
Profile